Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835093 | 0.86 | ALDH1A1 (0.79) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL6444189 | 0.86 | RAB9A (0.61) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL11654124 | 0.86 | RAB9A (0.71) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL474709 | 0.85 | KMT2A (0.70) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL6242208 | 0.84 | RAB9A (0.84) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL308570 | 0.84 | ALDH1A1 (0.77) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL7808621 | 0.83 | SMN1; SMN2 (0.70) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL24027984 | 0.83 | ALDH1A1 (0.64) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL677770 | 0.83 | RAB9A (1.00) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL20323586 | 0.83 | RAB9A (0.72) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3359542-B1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2020-11-12 | — | — | US | disclosed |
| US-10717742-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-07-21 | — | — | US | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| CN-107405337-A | Substituted chroman and application method | 艾伯维公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2017060431-A1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | WO | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| CN-101048388-A | Quinazolinone derivatives and their use as B-Raf inhibitors | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| US-4457940-A | Carboxylic acid ester derivatives, process for manufacturing said derivatives, insecticides and acaricides containing said derivatives, and method for killing insects and acarina by treating therewith | DAINIPPON JOCHUGIKU KABUSHIKI KAISHA (JP) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | RAB9A 2978/4885ALDH1A1 401/4885NPC1 2438/4885 |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | RAB9A 4148/4885ALDH1A1 1494/4885NPC1 1179/4885 |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | RAB9A 786/4885ALDH1A1 1780/4885NPC1 1861/4885 |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | TP53, MDM2, FOXM1 | RAB9A 1582/4885ALDH1A1 667/4885NPC1 3247/4885 |
| US-10717742-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | TP53, MDM2, FOXM1 | RAB9A 1502/4885ALDH1A1 978/4885NPC1 3512/4885 |
| US-10882866-B1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | TP53, MDM2, FOXM1 | RAB9A 1417/4885ALDH1A1 700/4885NPC1 3103/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | RAB9A 4301/4885ALDH1A1 2926/4885NPC1 1081/4885 |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | RAB9A 4060/4885ALDH1A1 4582/4885NPC1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.